Dogwood Therapeutics (DWTX) investor relations material

Company overview and business model

• Development-stage biopharma focused on medicines for cancer-treatment pain and peripheral neuropathy, with potential expansion into other pain conditions after clinical success.

• Halneuron, a NaV 1.7 modulator, is in Phase 2b for chronic pain after cancer chemotherapy; it has FDA Fast Track designation and prior Phase 2 evidence of pain reduction with an acceptable safety profile.

• SP16, a proprietary immunomodulatory and anti-inflammatory peptide, is poised to enter Phase 1 for chemotherapy-induced peripheral neuropathy; preclinical findings suggest potential neuroprotective effects.

Financial performance and metrics

• Forvis Mazars’ audit report on FY2025 and FY2024 consolidated financial statements contains an explanatory paragraph citing substantial doubt about the ability to continue as a going concern.

Use of proceeds and capital allocation

• The October 19, 2026 private placement generated approximately $5.0 million gross proceeds at $1.22 per share; proceeds are intended for general working capital.

• No proceeds will be received from Sealbond’s resales under this prospectus; the selling stockholder receives resale proceeds and pays its brokerage fees, commissions and similar selling expenses.

• Registration fees and expenses are payable by the issuer; estimated registration costs total $53,897.56, including legal, audit and transfer-agent expenses.